ANI Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ANI Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, ANI Pharmaceuticals generated $56.7 million of operating cash flow and spent $3.1 million on capital expenditures. That left free cash flow of $53.6 million, a free-cash-flow margin of 20.2% of revenue. Free cash flow was down 25.3% from the prior year's $71.8 million.
ANI Pharmaceuticals returned $813,000 to shareholders through share repurchases, equal to 2% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
ANI Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 24.71M | 29.49M | 27.49M | 26.62M | 8.55M | 15.68M | -10.28M | -24.17M | -2.29M | 18.21M | 1.16M | 9.94M |
| Net Income growth (YoY) | +189.05% | +88.07% | — | — | — | -13.87% | -989.70% | -343.12% | -136.62% | +1165.25% | — | — |
| Depreciation & Amortization | 19.64M | 20.92M | 22.61M | 22.63M | 23.28M | 22.89M | 22.60M | 15.75M | 14.70M | 14.69M | 15.19M | 15.21M |
| Stock-Based Compensation | 11.41M | 10.19M | 9.77M | 9.69M | 9.60M | 8.87M | 7.06M | 7.49M | 7.86M | 6.93M | 5.62M | 5.44M |
| Change in Working Capital | -19.89M | 30.45M | -31.36M | -21.36M | -3.32M | 6.71M | -33.01M | -1.00M | -6.43M | -1.45M | 14.94M | -2.61M |
| Operating Cash Flow | 56.67M | 58.38M | 30.37M | 44.05M | 75.81M | 34.99M | 15.86M | 12.47M | 17.41M | 18.27M | 44.74M | 32.17M |
| Capital Expenditures | -3.05M | -6.07M | -1.24M | -6.10M | -4.01M | -2.47M | -2.39M | -4.81M | -4.45M | -4.58M | -2.28M | -1.74M |
| Investing Cash Flow | -3.05M | -11.32M | -1.40M | -6.16M | -6.91M | -19.85M | -10.68M | -398.52M | -4.45M | 8.93M | -4.78M | -4.55M |
| Dividends Paid | 0 | 0 | 0 | -344.00K | -407.00K | -406.00K | -406.00K | -406.00K | -407.00K | -406.00K | -406.00K | -406.00K |
| Share Repurchases | -813.00K | -19.75M | -611.00K | -1.04M | -551.00K | -10.00M | -318.00K | -680.00K | -1.30M | -8.66M | -231.00K | -670.00K |
| Debt Repaid | — | — | — | — | — | — | — | — | -750.00K | -750.00K | -750.00K | -750.00K |
| Financing Cash Flow | -4.65M | -21.62M | -4.64M | 6.34M | -1.75M | -9.91M | -4.91M | 291.03M | -1.45M | -19.73M | -11.92M | 3.75M |
| Net Change in Cash | 49.03M | 25.59M | 22.98M | 44.81M | 68.00M | 4.94M | -123.00K | -95.09M | 11.51M | 7.48M | 28.04M | 31.37M |
| Free Cash Flow | 53.62M | 52.30M | 29.12M | 37.95M | 71.80M | 32.52M | 13.47M | 7.66M | 12.96M | 13.69M | 42.46M | 30.43M |
This table shows 12 quarterly periods of ANI Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ANIP's reporting calendar. What is a cash flow statement?